A review of the Bacillus Anthracis
Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
The Department of Health & Human Services (DHHS) recently solicited responses to a Request for Proposal (RFP) for 'Acquisition of Therapeutic Products for Treatment of Inhalational Anthrax Disease for the Strategic National Stockpile (SNS)' under which monoclonal antibodies will be selected and purchased to treat civilians in the event of a bioterror attack using Bacillus anthracis
Immune responses to Bacillus anthracis
protective antigen in patients with bioterrorism-related cutaneous or inhalational anthrax.
While this antibiotic is being developed for the treatment of serious infections caused by Vancomycin Resistant Enterococci (VRE), Methicillin Resistant Staphylococcus aureus (MSRA) and other organisms that are becoming increasingly resistant to available antibiotics, preclinical testing and analysis have shown the compound to be potent against Bacillus cereus, a sporeforming bacterium genetically similar to Bacillus anthracis
Three virulence factors account for majority of the clinical manifestations of Bacillus anthracis
and are edema toxin, lethal toxin and an antiphagocytic capsular antigen.
Evidence for plasmid-mediated toxin production in Bacillus anthracis
Following a directive from UVDI, researchers at Pennsylvania State University(1) have identified what they believe to be the most appropriate rate constant for killing Bacillus anthracis
using ultraviolet germicidal irradiation (UVGI).
Fluorescent detection techniques for real-time multiplex strand-specific detection of Bacillus anthracis
using rapid PCR.
These data provide some insight into the activity of antibiotics, such as clarithromycin, against Bacillus anthracis
and support further study of this drug against anthrax.
AVP 21D9 is a human monoclonal antibody to Bacillus anthracis
protective antigen (PA) that was discovered and developed by AVANIR Pharmaceuticals.
1) in this issue of Emerging Infectious Diseases describes the use of syndromic surveillance to detect inhalational anthrax resulting from a hypothetical covert release of Bacillus anthracis
spores at a major shopping mall.
The successful validation tests on the Bacillus anthracis
surrogate Bacillus subtilis, were conducted by Dr.